Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2024-12-31 Regulatory Filings
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Il-Yang Pharmaceutical regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to the investment period end date due to equipment delivery delays. Since this is a specific regulatory disclosure regarding capital expenditure and facility investment updates, it falls under the general regulatory filing category as it does not fit into specific categories like M&A, dividends, or share repurchases.
2024-12-31 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Ilyang Pharm Co., Ltd., covering the 3rd quarter of the 54th fiscal year (2024-01-01 to 2024-09-30). It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
신탁계약해지결과보고서
Regulatory Filings Classification · 100% confidence The document is a formal report filed with the Financial Supervisory Service (FSS) in South Korea regarding the termination of a trust contract for treasury shares (자기주식 특정금전신탁). It details the termination date, the financial institution involved, and the status of treasury shares held. This type of filing is a specific regulatory disclosure regarding corporate capital and share management, which falls under the 'Transaction in Own Shares' category as it relates to the disposal/termination of treasury share trust arrangements.
2024-11-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. It details share acquisitions (장내매수) by a director (CEO Jung Yoo-seok) of Ilyang Pharmaceutical Co., Ltd. This type of filing is specifically categorized as a Director's Dealing (DIRS) report, as it tracks insider transactions.
2024-10-18 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a '최대주주등소유주식변동신고서' (Report on Changes in Shareholding by Major Shareholders and Related Parties) filed by Il-Yang Pharmaceutical. This document details specific share transactions (purchases) made by a major shareholder/insider (Jung Yu-seok) and provides a summary of the total shareholding status of the major shareholders. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by individuals related to the company's management/major ownership.
2024-10-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details specific share transactions (장내매수 - open market purchases) made by a director (Jung Yu-seok) of the company (Ilyang Pharmaceutical). This is a standard regulatory filing for insider trading/director dealings.
2024-10-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.